Jim Cramer highlights JNJ as a top-tier defensive pick while signaling a buy for Eli Lilly after its recent dip, contrasting their growth profiles against the value-heavy outlook for Pfizer and Cardinal Health.
Jim Cramer calls it best of breed with AAA balance sheet and no drug expiration problems, preferring it over Lilly and Pfizer.
Cramer approves adding after a pullback and highlights Mounjaro/Zepbound as a multi-year franchise, with strong revenue growth.
Cramer acknowledges it as terrific with strong earnings momentum and a lower valuation.
Cramer needs a reason to recommend it; low valuation but uncertainty over patent losses and COVID revenue replacement.
Mad Money host Jim Cramer favors Johnson & Johnson for its AAA balance sheet and diversification, while endorsing Eli Lilly following a recent stock pullback. Cramer ranks the healthcare giants based on growth profiles and risk, noting that while Lilly leads in revenue expansion, JNJ offers superior stability. Pfizer remains a value play, though it faces ongoing uncertainty regarding patent expirations and COVID-era revenue replacement.
Cramer favors JNJ for its 'best of breed' status, citing its AAA balance sheet, broad diversification, and lack of immediate drug patent expiration concerns compared to the more concentrated growth model of Eli Lilly.
While Pfizer trades at a low forward P/E of 9.88, it is viewed as a value outlier due to uncertainty surrounding its ability to replace declining COVID-19 revenue and manage upcoming patent losses.